Warning: The NCBI web site requires JavaScript to function. more...
Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature.
Gupta D, Lis CG.
J Ovarian Res. 2009 Oct 9;2:13.
Related citations
Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer.
Kang WD, Choi HS, Kim SM.
Gynecol Oncol. 2010 Jan;116(1):57-60. Epub 2009 Oct 9.
Importance of CA125 normalization during neoadjuvant chemotherapy followed by planned delayed surgical debulking in patients with epithelial ovarian cancer.
Le T, Faught W, Hopkins L, Fung-Kee-Fung M.
J Obstet Gynaecol Can. 2008 Aug;30(8):665-70.
CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
Juretzka MM, Barakat RR, Chi DS, Iasonos A, Dupont J, Abu-Rustum NR, Poynor EA, Aghajanian C, Spriggs D, Hensley ML, Sabbatini P.
Gynecol Oncol. 2007 Jan;104(1):176-80. Epub 2006 Sep 25.
Serum CA125 assay at the time of relapse has no prognostic relevance in patients undergoing chemotherapy for recurrent ovarian cancer: a multicenter Italian study.
Gadducci A, Landoni F, Maggino T, Sartori E, Zola P, Ferdeghini M, Parma G, Cristofani R.
Int J Gynecol Cancer. 1997 Jan;7(1):78-83.
Significance of serum CA125 and TPS antigen levels for determination of overall survival after three chemotherapy courses in ovarian cancer patients during long-term follow-up.
van Dalen A, Favier J, Hallensleben E, Burges A, Stieber P, de Bruijn HW, Fink D, Ferrero A, McGing P, Harlozinska A, Kainz Ch, Markowska J, Molina R, Sturgeon C, Bowman A, Einarsson R, Goike H.
Eur J Gynaecol Oncol. 2009;30(6):609-15.
New tumor markers: CA125 and beyond.
Bast RC Jr, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, Baggerly KA, Atkinson EN, Skates S, Zhang Z, Lokshin A, Menon U, Jacobs I, Lu K.
Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:274-81. Review.
Tumor Markers in Ovarian Malignancies.
Eagle K, Ledermann JA.
Oncologist. 1997;2(5):324-329.
Serum CA125 level before the development of ovarian cancer.
Kobayashi H, Ooi H, Yamada Y, Sakata M, Kawaguchi R, Kanayama S, Sumimoto K, Terao T.
Int J Gynaecol Obstet. 2007 Nov;99(2):95-9. Epub 2007 Jul 23.
The lack of significance of Ca125 response in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking.
Le T, Hopkins L, Faught W, Fung-Kee-Fung M.
Gynecol Oncol. 2007 Jun;105(3):712-5. Epub 2007 Apr 2.
Correlations of serum CA125 level and computerized tomography (CT) imaging with laparotomic findings following intraperitoneal chemotherapy in patients with ovarian cancer.
Topuz E, Aydiner A, Saip P, Eralp Y, Taş F, Salihoğlu Y, Tenekeci N.
Eur J Gynaecol Oncol. 2000;21(6):599-602.
Prognostic value of CA125 kinetics and half-life in advanced ovarian cancer.
Colaković S, Lukiç V, Mitroviç L, Jeliç S, Susnjar S, Marinkoviç J.
Int J Biol Markers. 2000 Apr-Jun;15(2):147-52.
Comparison of tumor-associated trypsin inhibitor (TATI) with CA125 as a marker for diagnosis and monitoring of epithelial ovarian cancer.
Gadducci A, Ferdeghini M, Rispoli G, Prontera C, Bianchi R, Fioretti P.
Scand J Clin Lab Invest Suppl. 1991;207:19-24.
CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: a population-based study.
van Altena AM, Kolwijck E, Spanjer MJ, Hendriks JC, Massuger LF, de Hullu JA.
Gynecol Oncol. 2010 Nov;119(2):265-9. Epub 2010 Aug 24.
Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial.
Rustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC, Kristensen G, Mediola C, Coens C, Qian W, Parmar MK, Swart AM; MRC OV05; EORTC 55955 investigators.
Lancet. 2010 Oct 2;376(9747):1155-63.
Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker.
Canney PA, Moore M, Wilkinson PM, James RD.
Br J Cancer. 1984 Dec;50(6):765-9.
Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma.
Kudoh K, Kikuchi Y, Kita T, Tode T, Takano M, Hirata J, Mano Y, Yamamoto K, Nagata I.
Gynecol Obstet Invest. 1999;47(1):52-7.
CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use.
Duffy MJ, Bonfrer JM, Kulpa J, Rustin GJ, Soletormos G, Torre GC, Tuxen MK, Zwirner M.
Int J Gynecol Cancer. 2005 Sep-Oct;15(5):679-91.
Elevated serum levels of neopterin and soluble interleukin-2 receptor in patients with ovarian cancer.
Gadducci A, Ferdeghini M, Malagnino G, Prontera C, Fanucchi A, Annicchiarico C, Bianchi R, Fioretti P, Facchini V.
Gynecol Oncol. 1994 Mar;52(3):386-91.
The value of CA 125 and CA72-4 in management of patients with epithelial ovarian cancer.
Fayed ST, Ahmad SM, Kassim SK, Khalifa A.
Dis Markers. 1998 Nov;14(3):155-60.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on